Literature DB >> 16912218

Roles for the Trypanosoma brucei P2 transporter in DB75 uptake and resistance.

Charlotte A Lanteri1, Mhairi L Stewart, Janice M Brock, Vincent P Alibu, Steven R Meshnick, Richard R Tidwell, Michael P Barrett.   

Abstract

A novel trypanocide, 2,5-bis(4-amidinophenyl)furan (DB75), in its prodrug amidoxime-derivative form, 2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime (DB289), is in trials as the first orally administered drug for human African trypanosomiasis. DB75 is a diamidine. Resistance to some diamidines correlates to loss of uptake via the P2 aminopurine transporter. We show here that uptake of DB75 into Trypanosoma brucei also occurs principally via the P2 transporter. Uptake of tritiated DB75 occurred via a high-affinity (K(m app), 3.2 microM) carriermediated route that was inhibited by adenosine, adenine, and pentamidine, all known substrates of the P2 transporter. Trypanosomes lacking the TbAT1 gene that encodes the P2 transporter demonstrated an 11-fold reduction in sensitivity to DB75 when measured under controlled in vitro conditions. These knockout cells were also less sensitive to DB75 than wild-type cells in mice. Initial uptake rates of DB75 into the Deltatbat1 knockout cell line were greatly reduced compared with rates in wild-type cells. A trypanosome cell line selected in vitro for DB75 resistance was shown to have lost P2-mediated DB75 uptake. The TbAT1 gene was mapped to chromosome V of the T. brucei genome and the DB75-resistant parasites were shown to have deleted both alleles of this gene. Fluorescence microscopy of DB75-treated trypanosomes revealed that DB75 fluorescence localizes rapidly within the DNA-containing organelles of wild-type trypanosomes, whereas no fluorescence was observed in Deltatbat1-null parasites or in the parasites selected for resistance to DB75.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912218     DOI: 10.1124/mol.106.024653

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  25 in total

1.  The plasma membrane of bloodstream-form African trypanosomes confers susceptibility and specificity to killing by hydrophobic peptides.

Authors:  John M Harrington; Justin Widener; Natalie Stephens; Thomas Johnson; Maria Francia; Paul Capewell; Annette Macleod; Stephen L Hajduk
Journal:  J Biol Chem       Date:  2010-07-08       Impact factor: 5.157

2.  Pharmacokinetic comparison to determine the mechanisms underlying the differential efficacies of cationic diamidines against first- and second-stage human African trypanosomiasis.

Authors:  Sihyung Yang; Tanja Wenzler; Patrik N Miller; Huali Wu; David W Boykin; Reto Brun; Michael Zhuo Wang
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

3.  Two novel nucleobase/pentamidine transporters from Trypanosoma brucei.

Authors:  Diana Ortiz; Marco A Sanchez; Paula Quecke; Scott M Landfear
Journal:  Mol Biochem Parasitol       Date:  2008-10-17       Impact factor: 1.759

4.  Multiple genetic mechanisms lead to loss of functional TbAT1 expression in drug-resistant trypanosomes.

Authors:  Mhairi L Stewart; Richard J S Burchmore; Caroline Clucas; Christiane Hertz-Fowler; Karen Brooks; A Tait; A Macleod; C Michael R Turner; Harry P De Koning; Pui Ee Wong; Michael P Barrett
Journal:  Eukaryot Cell       Date:  2009-12-04

5.  Selective delivery of 2-hydroxy APA to Trypanosoma brucei using the melamine motif.

Authors:  Nina Klee; Pui Ee Wong; Beatriz Baragaña; Farah El Mazouni; Margaret A Phillips; Michael P Barrett; Ian H Gilbert
Journal:  Bioorg Med Chem Lett       Date:  2010-06-17       Impact factor: 2.823

6.  A molecular mechanism for eflornithine resistance in African trypanosomes.

Authors:  Isabel M Vincent; Darren Creek; David G Watson; Mohammed A Kamleh; Debra J Woods; Pui Ee Wong; Richard J S Burchmore; Michael P Barrett
Journal:  PLoS Pathog       Date:  2010-11-24       Impact factor: 6.823

7.  New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.

Authors:  Tanja Wenzler; David W Boykin; Mohamed A Ismail; James Edwin Hall; Richard R Tidwell; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

8.  Synthesis and activity of azaterphenyl diamidines against Trypanosoma brucei rhodesiense and Plasmodium falciparum.

Authors:  Laixing Hu; Reem K Arafa; Mohamed A Ismail; Alpa Patel; Manoj Munde; W David Wilson; Tanja Wenzler; Reto Brun; David W Boykin
Journal:  Bioorg Med Chem       Date:  2009-08-07       Impact factor: 3.641

9.  A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427.

Authors:  Melissa L Sykes; Vicky M Avery
Journal:  Parasit Vectors       Date:  2009-11-12       Impact factor: 3.876

10.  Genotypic status of the TbAT1/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from Northwestern Uganda following melarsoprol withdrawal.

Authors:  Anne J N Kazibwe; Barbara Nerima; Harry P de Koning; Pascal Mäser; Michael P Barrett; Enock Matovu
Journal:  PLoS Negl Trop Dis       Date:  2009-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.